| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Pharmacology & Physiology, UMDNJ-New Jersey Medical School, Newark, New Jersey, United States
2 Newark, New Jersey, United States; Pharmacology & Physiology, UMDNJ-New Jersey Medical School, Newark, New Jersey, United States
3 Surgery, UMDNJ-New Jersey Medical School, Newark, New Jersey, United States
4 Ciencias Fisiologicas, P. Universidad Catolica de Chile, Santiago, RM, Chile
5 Pharmacology and Physiology, MSB H-609, New Jersey Medical School, Newark, New Jersey, United States
* To whom correspondence should be addressed. E-mail: sanchefa{at}umdnj.edu.
Nitric oxide (NO) regulates flow and permeability. Acetylcholine (ACh) and platelet-activating factor (PAF) lead to eNOS phosphorylation and NO release. While ACh causes only vasodilation, PAF induces vasoconstriction and hyperpermeability. The key differential signaling mechanisms for discriminating between vasodilation and hyperpermeability are unknown. We tested the hypothesis that differential translocation may serve as a regulatory mechanism of eNOS to determine specific vascular responses. We used ECV-304 cells permanently transfected with eNOS-green fluorescent protein (ECVeNOS-GFP) and demonstrated that the agonists activate eNOS and reproduce their characteristic endothelial permeability effects in these cells. We evaluated eNOS localization by lipid raft analysis and immunofluorescence microscopy. After PAF and ACh, eNOS moves away from caveolae. eNOS distributes both in the plasma membrane and Golgi in control cells. ACh (10-5 M, 10-4 M) translocated eNOS preferentially to the Trans Golgi network (TGN) and PAF (10-7 M) preferentially to the cytosol. We suggest that PAF-induced eNOS translocation preferentially to cytosol reflects a differential signaling mechanism related to changes in permeability, whereas ACh-induced eNOS translocation to the TGN is related to vasodilation.
This article has been cited by other articles:
|
|
 |
|
  F. A. Sanchez, R. Rana, D. D. Kim, T. Iwahashi, R. Zheng, B. K. Lal, D. M. Gordon, C. J. Meininger, and W. N. Duran Internalization of eNOS and NO delivery to subcellular targets determine agonist-induced hyperpermeability PNAS, April 21, 2009; 106(16): 6849 - 6853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Sanchez, D. D. Kim, R. G. Duran, C. J. Meininger, and W. N. Duran Internalization of eNOS via caveolae regulates PAF-induced inflammatory hyperpermeability to macromolecules Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1642 - H1648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Leary, S. Rajasekaran, R. R. Morrison, E. I. Tuomanen, T. K. Chin, and P. A. Hofmann A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2775 - H2784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Dudzinski and T. Michel Life history of eNOS: Partners and pathways Cardiovasc Res, July 15, 2007; 75(2): 247 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Kim, F. A. Sanchez, R. G. Duran, T. Kanetaka, and W. N. Duran Endothelial nitric oxide synthase is a molecular vascular target for the Chinese herb Danshen in hypertension Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2131 - H2137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Boerrigter, L. C. Costello-Boerrigter, A. Cataliotti, H. Lapp, J.-P. Stasch, and J. C. Burnett Jr Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure Hypertension, May 1, 2007; 49(5): 1128 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Yuan New insights into eNOS signaling in microvascular permeability Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1029 - H1031. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
